CENTOGENE shares start trading at NASDAQ

CENTOGENE Reveals Growth of Rare Hereditary Disease Knowledge Base

CENTOGENE Accelerates Rare Disease Diagnosis with new Artificial Intelligence Solution

CORUS incorporates three targets in Iberia